Ozempic for Weight Loss: The Off-Label Evidence, Explained

What "Off-Label" Means for Ozempic and Weight Loss

Off-label prescribing is the practice of using an FDA-approved drug for an indication, dose, or population not specified on its product label. This is legal, common, and sometimes well-supported by evidence. Ozempic falls squarely into this category when prescribed for weight loss.

The FDA approved Ozempic in December 2017 as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes [1]. Its label makes no mention of obesity or weight management as an indication. Novo Nordisk later developed Wegovy (semaglutide 2.4 mg), which the FDA approved in June 2021 specifically for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity [2].

Both drugs contain the same molecule. The difference is dose and regulatory approval. Ozempic maxes out at 2.0 mg per week. Wegovy reaches 2.4 mg per week. When a physician writes an Ozempic prescription for a patient without type 2 diabetes who wants to lose weight, that prescription is off-label by definition. An estimated 40 to 60% of semaglutide prescriptions during the 2022 to 2024 shortage period were for off-label weight management, according to pharmacy benefit analyses reported by multiple insurers.

The American Gastroenterological Association's 2022 clinical practice guideline on pharmacological management of obesity recommends semaglutide 2.4 mg (the Wegovy dose) as a first-line pharmacotherapy option for adults with obesity [3]. The guideline does not specifically endorse the lower Ozempic doses for this purpose, creating a gap between clinical practice and formal guideline support.

Weight Loss Data from the SUSTAIN Trials (Ozempic Doses)

The SUSTAIN program tested semaglutide at 0.5 mg and 1.0 mg weekly in patients with type 2 diabetes. Weight loss was a secondary endpoint. The results were consistent across trials: patients lost meaningful weight even though the studies were designed to measure glucose control.

In SUSTAIN 1 (N=388), semaglutide 0.5 mg produced 3.7 kg mean weight loss and semaglutide 1.0 mg produced 4.5 kg mean weight loss over 30 weeks, versus 1.0 kg with placebo [4]. SUSTAIN 6 (N=3,297), a cardiovascular outcomes trial running 104 weeks, demonstrated sustained weight reductions of 3.6 kg with 0.5 mg and 4.9 kg with 1.0 mg compared with placebo [5]. These patients had established cardiovascular disease or cardiovascular risk factors alongside their diabetes diagnosis.

The weight loss observed at Ozempic-range doses (0.5 to 1.0 mg) is real but modest compared to the 2.4 mg dose studied in the STEP program. A patient on Ozempic 1.0 mg might expect roughly 5% total body weight loss. That figure is clinically meaningful by FDA standards (the threshold for approval is typically 5% or greater) but substantially less than the 15% achievable at the higher Wegovy dose.

Novo Nordisk later introduced the 2.0 mg Ozempic dose, which received FDA approval for type 2 diabetes in March 2022. No dedicated obesity trial has studied the 2.0 mg dose in patients without diabetes. Weight loss at 2.0 mg can be estimated from dose-response modeling and clinical experience to fall somewhere between the 1.0 mg and 2.4 mg results.

The STEP Trials: What Semaglutide 2.4 mg Actually Proved

The STEP program provides the strongest evidence for semaglutide as a weight-loss drug. These trials tested the 2.4 mg weekly dose (branded as Wegovy) in adults with overweight or obesity, most without type 2 diabetes.

STEP-1 (N=1,961) randomized adults with BMI of 30 or higher (or 27 with a comorbidity) to semaglutide 2.4 mg or placebo for 68 weeks. The semaglutide group lost 14.9% of body weight versus 2.4% with placebo (P<0.001) [6]. One-third of patients on semaglutide lost 20% or more of their starting weight. That result changed the obesity treatment field overnight.

STEP-2 (N=1,210) tested the same dose in adults with type 2 diabetes and obesity. Weight loss was 9.6% with semaglutide 2.4 mg, versus 3.4% with placebo at 68 weeks [7]. The blunted response in diabetes patients is well-documented across GLP-1 receptor agonist trials. STEP-3 (N=611) combined semaglutide 2.4 mg with intensive behavioral therapy and an initial low-calorie diet, producing 16.0% weight loss versus 5.7% with placebo [8].

STEP-5 extended the treatment period to two years and confirmed durability: participants maintained 15.2% body weight reduction at 104 weeks versus 2.6% with placebo [9]. Weight regain after stopping semaglutide, however, has been substantial. STEP-4 (N=902) showed that patients who switched from semaglutide to placebo at week 20 regained roughly two-thirds of lost weight by week 68, while those who continued semaglutide lost an additional 7.9% [10].

Dr. Robert Kushner, a professor of medicine at Northwestern University and an investigator in the STEP program, has stated: "Semaglutide 2.4 mg represents a new era in obesity pharmacotherapy, with weight loss approaching what we previously only saw with bariatric surgery."

SELECT: Cardiovascular Outcomes in Obesity Without Diabetes

The SELECT trial (N=17,604) tested semaglutide 2.4 mg in adults with established cardiovascular disease and a BMI of 27 or higher, but without diabetes. Over a mean follow-up of 39.8 months, semaglutide reduced the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 20% (HR 0.80 to 95% CI 0.72, 0.90, P<0.001) [11].

This trial matters for off-label Ozempic discussions because it demonstrated that the cardiovascular benefit of semaglutide in people with obesity is independent of glucose-lowering. SELECT enrolled patients without diabetes. The weight loss observed (mean 9.4% at 104 weeks) likely contributed to the cardiovascular risk reduction, though the mechanisms probably extend beyond weight loss alone (reduced systemic inflammation, improved endothelial function, decreased visceral adiposity).

The American Heart Association recognized these findings as practice-changing. Dr. A. Michael Lincoff, the trial's principal investigator, noted: "SELECT establishes that treating obesity with semaglutide reduces hard cardiovascular events regardless of diabetes status."

No equivalent cardiovascular outcomes trial exists for the lower Ozempic doses (0.5 to 1.0 mg) in patients without diabetes. SUSTAIN 6 showed cardiovascular safety at Ozempic doses in patients with type 2 diabetes, but the population and context differ from SELECT.

Why Physicians Prescribe Ozempic Instead of Wegovy

If Wegovy is the FDA-approved product for weight loss, why do clinicians reach for Ozempic? The reasons are practical, not scientific.

Supply shortages have plagued Wegovy since its launch. Novo Nordisk struggled to meet demand, and the FDA placed Wegovy on its drug shortage list intermittently between 2022 and 2025. When patients cannot fill a Wegovy prescription, prescribers may switch to Ozempic as an available alternative containing the same active molecule.

Insurance coverage is the second driver. Many commercial plans and pharmacy benefit managers cover Ozempic for type 2 diabetes but exclude Wegovy or impose strict prior authorization for anti-obesity medications. A physician might diagnose a patient with type 2 diabetes (if present) and prescribe Ozempic within its labeled indication, knowing the patient will also benefit from weight loss. This practice sits on the boundary between on-label and off-label prescribing, depending on the clinical documentation.

Cost without insurance is the third factor. Ozempic and Wegovy carry similar list prices (approximately $900, $1,350 per month), but manufacturer savings programs, copay cards, and formulary placement can make one or the other cheaper for a given patient at a given pharmacy.

None of these reasons change the regulatory or clinical reality: prescribing Ozempic to a patient without type 2 diabetes for the purpose of weight loss remains off-label. The prescriber bears responsibility for informed consent and documentation of the clinical rationale.

Safety Profile at Ozempic Doses

The safety data for semaglutide at 0.5 to 2.0 mg come primarily from the SUSTAIN program and post-marketing surveillance. Gastrointestinal events are the most common adverse effects: nausea (15 to 20%), diarrhea (8 to 12%), vomiting (5 to 9%), and constipation (5 to 7%) [4]. These effects are dose-dependent and typically peak during the dose-escalation phase.

Serious but less common risks include:

Pancreatitis. Acute pancreatitis has been reported with GLP-1 receptor agonists. The Ozempic prescribing information carries a precaution, though pooled trial data suggest the absolute incidence is low (roughly 0.1 to 0.3% per year) [1].

Gallbladder disease. Rapid weight loss increases cholelithiasis risk. In the STEP program, gallbladder-related events occurred in approximately 2.6% of semaglutide-treated patients versus 1.2% on placebo [6].

Thyroid C-cell tumors. Semaglutide carries a boxed warning based on rodent studies showing thyroid C-cell tumors at clinically relevant exposures. No causal link has been established in humans, but the drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [1].

Diabetic retinopathy complications. SUSTAIN 6 found an unexpected increase in retinopathy complications with semaglutide versus placebo (HR 1.76) in patients with type 2 diabetes [5]. This may relate to rapid glycemic improvement rather than a direct drug effect, and it applies primarily to patients with pre-existing retinopathy.

For patients without diabetes using Ozempic off-label, the retinopathy signal is less relevant, but the GI, gallbladder, and pancreatitis risks remain. No long-term safety trial has specifically evaluated Ozempic-range doses in a non-diabetic obesity population.

Evidence Grading: How Strong Is the Case?

Applying the GRADE framework to off-label Ozempic for weight loss produces a nuanced picture. The evidence quality depends on which specific question you ask.

For semaglutide 2.4 mg (Wegovy) in obesity: High certainty. Multiple large randomized controlled trials (STEP 1, 5, SELECT) with consistent, large effect sizes and hard clinical endpoints [6][7][8][9][10][11].

For semaglutide 0.5 to 1.0 mg (standard Ozempic doses) in obesity without diabetes: Low to moderate certainty. Weight loss data come from secondary endpoints in diabetes trials. No dedicated Phase 3 obesity trial exists for these doses in non-diabetic populations. The biological plausibility is strong (same mechanism, same molecule, dose-response relationship), but the direct evidence base is thin.

For semaglutide 2.0 mg (highest Ozempic dose) in obesity without diabetes: Very low certainty. This dose was approved for diabetes based on the SUSTAIN FORTE trial and has no dedicated weight-loss trial data in non-diabetic populations [12].

The practical implication: a prescriber choosing Ozempic for weight loss is extrapolating from strong semaglutide 2.4 mg data down to lower doses, with reasonable biological justification but without the direct trial evidence that Wegovy's label carries.

Dosing Considerations for Off-Label Weight Loss

The standard Ozempic titration for type 2 diabetes starts at 0.25 mg weekly for four weeks, then increases to 0.5 mg. Further escalation to 1.0 mg and then 2.0 mg depends on glycemic response and tolerability. Prescribers using Ozempic off-label for weight loss generally follow the same slow titration schedule, which reduces GI side effects.

A dose-response relationship exists for weight loss with semaglutide. Higher doses produce greater weight reduction, but with diminishing returns and increasing side-effect burden. Most clinicians titrating Ozempic for weight loss aim for 1.0 mg or 2.0 mg weekly as the maintenance dose, recognizing that even 2.0 mg falls below the 2.4 mg dose proven in STEP trials.

The Endocrine Society's 2015 clinical practice guideline on pharmacological management of obesity recommends considering medications approved for long-term weight management in adults with BMI of 30 or higher, or 27 or higher with complications [13]. The guideline does not address off-label dosing of diabetes-approved GLP-1 agonists for obesity, a gap that predates the STEP data.

Patients and prescribers should discuss the off-label nature of the prescription, the evidence supporting semaglutide at the specific dose being prescribed, realistic expectations for weight loss (5 to 10% at Ozempic doses versus 15% at the Wegovy dose), and the need for ongoing lifestyle modification to maintain results.

Weight Regain After Stopping Semaglutide

Weight regain is the defining challenge of pharmacological obesity treatment, and semaglutide is no exception. STEP-4 demonstrated that patients who discontinued semaglutide after 20 weeks regained approximately 11.6% of body weight over the following 48 weeks, while those continuing treatment lost an additional 7.9% [10].

A one-year follow-up analysis of STEP-1 participants showed that one year after stopping semaglutide, participants had regained two-thirds of the weight they lost during the 68-week treatment period [6]. This pattern mirrors what has been observed with other anti-obesity medications and underscores that obesity is a chronic disease requiring sustained treatment.

For patients using off-label Ozempic, this has specific implications. A prescriber cannot guarantee long-term access to an off-label medication the same way they might for an on-label one. Insurance coverage can change, prior authorizations can be denied on renewal, and supply disruptions can interrupt treatment. Any of these scenarios may force an abrupt or involuntary discontinuation, triggering weight regain.

Current AGA guidelines recommend continuing anti-obesity pharmacotherapy long-term in patients who respond to treatment, provided the benefit-risk profile remains favorable [3]. Stopping semaglutide should involve a planned discussion about weight-regain risk and strategies to attenuate it, including caloric monitoring and structured physical activity.